Next, we observed that CD36 in primary SDH-deficient GIST cells (patients #3 and #4) could be inhibited by olverembatinib but not other TKIs used in the clinic (Fig. 4f). This evidence concerns the gene CD36 and gastrointestinal stromal tumor.